45~55 岁女性慢性病共病多重用药风险及管理模式研究*

薛允莲 ,  叶晋奇 ,  黄翊可 ,  刘贵浩

中国卫生统计 ›› 2026, Vol. 43 ›› Issue (4) : 567 -572.

PDF (1746KB)
中国卫生统计 ›› 2026, Vol. 43 ›› Issue (4) : 567 -572. DOI: 10.11783/j.issn.1002-3674.2026.04.016
应用研究

45~55 岁女性慢性病共病多重用药风险及管理模式研究*

作者信息 +

Author information +
文章历史 +
PDF (1787K)

摘要

目的 阐明45~55岁女性共病谱、多重用药现状及其对疗效的影响,提出管理模式优化框架。方法 依托 广东省某三级医院45~55 岁女性电子病历数据,采用Python 软件的Pyecharts 程序包纳入观察期望比(observed/expected ratios,O/E)值>1 的共病对构建共病关联网络,通过logistic 回归分析多重用药风险因素及其对疗效的影响,并整合分析结 果提出管理模式框架。结果 共纳入患者慢性病中位数为3 种(IQR:2~4),多重用药率(≥5 种药物)达79.15%(中位数11 种,IQR:5~18)。共病网络显示骨/软骨病-恶性肿瘤(O/E=2.16,n=1013)、甲状腺疾病-良性肿瘤(O/E=1.78,n=390)、高血 压-甲状腺疾病(O/E=1.13,n=379)、高血压-糖尿病(O/E=1.88,n=349)、高血压-代谢紊乱(O/E=1.47,n=307)为关键共病 对。logistic回归提示,高血压合并糖尿病(OR=3.173,95%CI:1.933~5.207)及共病数量(OR=1.242,95%CI:1.183~1.303)显 著增加多重用药风险,多重用药(OR=1.188,95%CI:1.043~1.354)是疗效降低的独立影响因素。结论 45~55 岁女性多处 于围绝经期,普遍存在共病及多重用药现象,给疗效造成潜在风险,亟需构建以关键共病对识别、用药风险评估及疗效动 态监测为核心的围绝经期女性慢性病共病管理模式。

关键词

围绝经期 / 慢性病共病 / 多重用药 / 管理模式

Key words

引用本文

引用格式 ▾
薛允莲,叶晋奇,黄翊可,刘贵浩. 45~55 岁女性慢性病共病多重用药风险及管理模式研究*[J]. 中国卫生统计, 2026, 43(4): 567-572 DOI:10.11783/j.issn.1002-3674.2026.04.016

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Matalliotakis M, Matalliotaki C, Krithinakis K, et al. Anatomic Distribution of Benign Ovarian Tumors in Perimenopausal and Postmenopausal Women [J].Cureus, 2023, 15(1): e34059.

[2]

Xu XL, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort [J].Hum Reprod, 2020, 35(1): 203-211.

[3]

Lleal M, Baré M, Ortonobes S, et al. Comprehensive Multimorbidity Patterns in Older Patients Are Associated with Quality Indicators of Medication—MoPIM Cohort Study [J].Int J Environ Res Public Health, 2022, 19(23): 15902.

[4]

曹丰,陈蕊,王小宁,等. 中国老年疾病临床多中心报告[J].中华老年多器官疾病杂志, 2018, 17(11):801-808.

[5]

刘葳,于德华,金花,等. 社区老年多病共存患者多重用药情况评价研究[J].中国全科医学, 2020, 23(13):1592-1598.

[6]

Masnoon N, Shakib S, Kalisch—Ellett L, et al. What is polypharmacy? A systematic review of definitions [J].BMC Geriatr, 2017, 17(1): 230.

[7]

广东省卫生健康委政务服务中心. 广东省医疗机构统计报表制度(2012年版)[R].2012.

[8]

杨青青,何航帜,李莉芳,等. 复杂网络社区发现视角下慢性阻塞性肺疾病患者的共病特征分析[J].中国卫生统计, 2024, 41(2): 181-184.

[9]

Ma B, Wang H, Dsouza M, et al. Geographic Patterns of Co—Occurrence Network Topological Features for Soil Microbiota at Continental Scale in Eastern China [J].ISME J, 2016, 10(8): 1891-1901.

[10]

刘贵浩,薛允莲,王晟,等. 某医院老年住院患者疾病累及系统数及死亡风险评估[J].中国医院统计, 2021, 28(2):149-152.

[11]

Hu X, Huang J, Lv Y, et al. Status of prevalence study on multimorbidity of chronic disease in China: systematic review [J].Geriatr Gerontol Int, 2015, 15(1): 1-10.

[12]

Fortin M, Lapointe L, Hudon C, et al. Multimorbidity and quality of life in primary care: a systematic review [J].Health Qual Life Outcomes, 2004, 2: 51.

[13]

王双养,王芳,吴福婷,等. 老年功能性消化不良患者多重用药负担及相关因素分析[J].中国卫生统计, 2021,38(3):432-435.

[14]

Fan J, Sun Z, Yu C, et al. Multimorbidity patterns and association with mortality in 0. 5 million Chinese adults [J].Chin Med J (Engl), 2022, 135(6): 648-657.

[15]

崔春子,杨土保. 我国中老年人群慢性病共病模式及影响因素探究:基于系统聚类和Apriori 算法[J].中国卫生统计,2023,40(2): 172-177.

[16]

Bao Y, Lu P, Wang M, et al. Exploring multimorbidity profiles in middle—aged inpatients: a network—based comparative study of China and the United Kingdom [J].BMC Med, 2023, 21(1): 495.

[17]

Camon C, Garratt M, Correa SM. Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause [J].Nat Aging, 2024, 4(12): 1731-1744.

[18]

Tran TXM, Kim S, Park B. Changes in metabolic syndrome and the risk of breast and endometrial cancer according to menopause in Korean women [J].Epidemiol Health, 2023, 45: e2023049.

[19]

Nicholson K, Liu W, Fitzpatrick D, et al. Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review [J].Lancet Healthy Longev, 2024, 5(4): e287-e296.

[20]

Farooq J, Sana MM, Chetana PM, et al. Polypharmacy in chronic liver disease patients: Implications for disease severity, drug—drug interaction, and quality of life [J].Saudi Pharm J, 2023, 31(8): 101668.

[21]

McCracken R, McCormack J, McGregor MJ, et al. Associations between polypharmacy and treatment intensity for hypertension and diabetes: a cross—sectional study of nursing home patients in British Columbia, Canada [J].BMJ Open, 2017, 7(8): e017430.

[22]

Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [J].Eur Heart J, 2021, 43(34): 3227-3337.

[23]

American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 [J].Diabetes Care, 2025, 48(Suppl 1): S181-S206.

[24]

Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed [J].Cancer, 2017, 123(3): 372-381.

[25]

Persani L, Brabant G, Dattani M, et al. 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism [J].Eur Thyroid J, 2018, 7(2): 55-66.

[26]

McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study: a controlled trial of an electronic decision support tool for deprescribing in acute care [J].J Am Geriatr Soc, 2019, 67(9): 1843-1850.

[27]

Lopez—Rodriguez JA, Rogero—Blanco E, Aza—Pascual—Salcedo M, et al. Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross—sectional study [J].PLoS One, 2020, 15(8): e0237186.

[28]

刘贵浩,薛允莲. 老年慢性病共病人群自我医疗的研究进展[J].慢性病学杂志, 2023,24(3):365-368.

[29]

Donaldson LJ, Kelley ET, Dhingra—Kumar N, et al. Medication without harm. WHO’s third global patient safety challenge [J].Lancet, 2017, 389(10080): 1680-1681.

[30]

Wu H, O’Donnell LK, Fujita K, et al. Deprescribing in the Older Patient: A Narrative Review of Challenges and Solutions [J].International Journal of General Medicine, 2021, 14: 3793-3807.

[31]

Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) [J].Fertil steril, 2001, 76(5):874-878.

基金资助

广东省基础与应用基础研究基金(2025A1515012867;2024A1515011745)

广东省哲学社会科学规划项目(GD24CGL39)

广东省卫生经济学会科研课题(2024-WJZL-01;2024-WJMZ-96;2024-WJMF-02)

AI Summary AI Mindmap
PDF (1746KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉